Role of Salbutamol and Furosemide in TTN

Phase 3

Completed

• Conditions: Transient Tachypnea of the Newborn
• Interventions: Drug: Furosemide Injection

• Registration Number: NCT03208894
• Lead Sponsor: Armed Forces Hospital, Pakistan

Brief Summary

to see the effects of slabutamol and IV furosemide in the treatment of transient tachypnea of newborn

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-01
• Primary Completion: 2017-05-30
• Study Completion: 2017-06-30
• Status Verified: 2017-07
• Study First Submitted: 2017-07-01
• Study First Submitted QC: 2017-07-05
• Last Update Submitted: 2017-07-05
• Study First Posted: 2017-07-06
• Last Update Posted: 2017-07-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• all newborn babies with clinically diagnosed TTN

Exclusion Criteria

• babies less than 34 weeks babies with congenital malformations and CHD

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
both furosemide and salbutamol	Furosemide Injection	-
with furosemide	Furosemide Injection	-
with salbutamol	Furosemide Injection	-

Primary Outcome Measures

Name	Time	Method
duration of oxygen requiremment in neonates having TTN.	upto 6 months	neonates will be subjected to treatment with furosemide and sabutamol and the duration of oxygen dependecy will be assessed.

Trial Locations

Locations (2)

Department of Pediatrics; 🇵🇰 Rawalpindi, Punjab, Pakistan

Military Hospital; 🇵🇰 Rawalpindi, Punjab, Pakistan